The Segal Cancer Centre has been forging partnerships with other provincial, national and international research groups as part of its commitment to conducting cutting-edge fundamental, translational and clinical research in cancer and providing training for the next generation of cancer researchers.
The large majority of the researchers working at the Segal Cancer Centre are affiliated to one of the many divisions of the Gerald Bronfman Department of Oncology at McGill University. Its faculty members include researchers and clinicians dedicated to understanding, preventing, treating and curing cancer, as well as improving the quality of life of individuals with cancer throughout the disease trajectory.
The TransMedTech Institute was created in 2016 following the award of a large grant from Apogée Canada Research Excellence Fund, based on a partnership of 5 founding institutions in Montreal. The main aim of the iTMT is to shape the future of the medical technology industry for complex diseases in all age groups, specifically through the acceleration of the development of new technologies or medical interventions, within a transdisciplinary and intersectoral ecosystem of open innovation (Living Lab). The medical technologies supported by iTMT focus on the diagnosis, prognosis, intervention and rehabilitation for people with serious illnesses including cancer. It is also part of its mission to facilitate validation, transfer, adoption by users and implementation of these technologies in the health system and / or the medical technology industry, and thus have a significant impact on health, the industrial sector of medical technologies, the training of the highly qualified personnel of tomorrow, and society.
RRCancer network, one of the thematic networks supported by the FRQS, aims to create new opportunities for research in order to improve diagnosis, prognosis, as well as health care and services to cancer patients. The network brings together researchers working in several areas of fundamental or translational and clinical research, student pathologists and research professionals from all hospital teaching centers and Quebec universities. The RRCancer network stimulates multidisciplinary research to prevent cancer and improve therapeutic approaches, while playing an important role in the training of specialized personnel and graduate students.
Since its creation, the RRCancer has directly supported the bio-banking of three main types of cancer (breast, ovary and hematology) by offering an important infrastructure for all cancer biobanks in Quebec. This infrastructure is at the very heart of the RRCancer, and is the reason for its inclusion in several major structuring projects in translational research or in clinical trials requiring the banking and / or use of biological material and data.
Q-CROC is a multidisciplinary and multi-institutional group of specialists whose main objectives are to enhance the Quebec clinical research infrastructure and capacity, to implement a translational research network focusing on therapeutic resistance in metastatic disease and to expand public awareness about clinical trials as a means of enhancing participation and recruitment. QCROC was awarded a Quebec-based grant to support expansion of the ‘next generation’ biopsy based clinical trials focused on identifying molecular signatures of therapeutic resistance to various treatments. QCROC was designated as the representative organization for all Quebec in the 3CTN.
The WIN was formed in 2009 to promote research and the development of personalized medicine for the treatment of cancer. Launched at the inaugural symposium in July 2009, the consortium brings together dozens of major cancer centres from around the globe, to focus on accelerating the evolution and implementation of Personalized Medicine; this includes developing and implementing a highly innovative clinical trial called WINTHERa study that evaluates the use of DNA sequencing and RNA expression to guide treatment recommendation, leading to an improved patient outcome and expanded benefits of personalized treatment.
The Quebec Cancer Consortium (QCC)
The QCC, an innovation pole in oncology, was built on alliances established between six of the largest hospitals and oncology research centers of McGill University and the University of Montreal. With the collaboration of several members of the Segal Cancer Centre, the QCC aims to standardize and harmonize best practices in oncology between hospitals and research centers, promote a patient-centered approach to increase patient recruitment in advanced clinical trials in oncology, and build longitudinal collections of biological samples from cancer patients and annotated clinical data.
Canadian Cancer Clinical Trials Network (3CTN)
The 3CTN is a pan-Canadian initiative to improve recruitment and the efficiency and quality of academic clinical trials in Canada. 3CTN’s leadership strongly believes in the value of patient and public involvement (PPI) and is committed to ensuring that PPI is embedded in every aspect of the 3CTN framework, both at the Coordinating Centre level and at Network sites across the country. One key part of 3CTN’s PPI efforts are the recruitment of Patient Representatives, who contribute a crucial perspective to clinical trials by providing feedback, insight, expertise and support towards trial activities and initiatives.
This public-private project unites academic and clinical institutions across Canada, pharma and biotech companies and public and private peer-funding agencies to support a large initiative in personalized Medicine. The “Personalize My Treatment’ project is a large prospective longitudinal program to collect molecularly profiled bio specimens and clinical data on many thousands of Canadian patients, with the aim of building an enormous platform for clinical trial matching, post-marketing pharmaco vigilance and scientific inquiry.
Over 120 cancer centers and other organizations around the world clustered in this multicenter cohort study to collect data and disseminate prospective, granular, uniformly organized information about patients with cancer who have been diagnosed with COVID-19. To date, the CCC19 project has gathered data from over 8000 cases and published several high impact papers.